kh-1060 and Lichen-Planus

kh-1060 has been researched along with Lichen-Planus* in 2 studies

Trials

2 trial(s) available for kh-1060 and Lichen-Planus

ArticleYear
KH 1060 for the treatment of lichen planus: a multicenter, randomized, double-blind, vehicle-controlled study.
    Archives of dermatology, 2000, Volume: 136, Issue:10

    Topics: Calcitriol; Double-Blind Method; Humans; Immunosuppressive Agents; Lichen Planus; Pharmaceutical Vehicles

2000
The epidermis of chronic idiopathic lichen planus during topical treatment with the vitamin D3 analogue KH 1060.
    Clinical and experimental dermatology, 1998, Volume: 23, Issue:1

    A parallel-group, double-blind, randomised study was performed to establish the effect of the vitamin D3 analogue KH 1060, in an ointment versus vehicle only, on the epidermal cell characteristics of chronic idiopathic lichen planus; KH 1060 also has marked immunosuppressive activity. A group of 10 patients were treated for 8 weeks with either KH 1060 ointment or vehicle only. In addition to the assessment of clinical scores, keratotome biopsies were taken before and after 8 weeks' treatment. Epidermal cell suspensions were prepared with trypsin and the suspensions incubated with TO-PRO-3 (DNA marker), RKSE 60 (marker for keratin 10-positive cells) and antivimentin (marker for all non-keratinocytes). In nine of the 10 patients, keratotome biopsies were obtained both before and after 8 weeks treatment. The vehicle alone had no significant effect on the clinical severity scores or epidermal cell characteristics. In contrast, the KH 1060 ointment resulted in a statistically significant reduction in the percentage of cells in S- and G2M phase and the percentage of vimentin-positive cells, but it did not affect the percentage of keratin 10-positive cells.

    Topics: Calcitriol; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Keratinocytes; Lichen Planus; Male; Middle Aged; Mitosis; S Phase; Skin

1998